Our sickle cell center offers many different clinical research trials to help improve the lives and find new treatments for those individuals living with sickle cell disease.
Karen Hawkins: Sickle Cell Research Program Manager
Brandi Day: Research Coordinator
Cheryl Alston: Research Coordinator
Joannie Hayes: Research Coordinator
Jkeonye Moss: Sickle Cell State Coordinator
Reset Trial: Phase III study for children and adults to evaluate the use of a new IV medication (Rivapansel) to decrease pain and hospitalization in patients with sickle cell disease
FIRST: Phase III study to evaluate the use of a new iron chelator (Ferriprox) for patients with sickle cell disease and iron overload
HGB206: Phase I gene therapy and autologous transplant study
STRIDE: A bone marrow transplant study to evaluate outcomes in patients with sickle cell disease undergoing bone marrow transplant compared to standard of care
Calypso: A Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an improved Deferasirox Formulation (granules) in Pediatric Patients with Iron Overload.
GBT440-025: Phase II, Open-label, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease and Severe Anemia.
SGHY-001-A: Phase I, Open-label Safety Study of SANGUINATE Infusion in Patients with Acute Severe Anemia who are unable to receive Red Blood Cell Transfusion.
STAR- A: Multi-Center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: A sickle Transplant Alliance for Research (STAR) Project.
Advocacy & Outreach
The Lifespan Comprehensive Sickle Cell Center at MUSC Children's Health is working closely with our local foundations and national organizations to raise awareness and advocacy for sickle cell disease as well as to improve funding for this underserved condition.
(SC)2: Sickle Cell-South Carolina
(SC)2 is a program funded through the Duke Endowment Foundation to create a state network for sickle cell disease to improve the care for individuals living with sickle cell disease throughout the state through increased access to care, communication between providers, and partnerships.
(SC)2 Principal Investigator: Julie Kanter
(SC)2 Program Coordinator: Jkeonye Moss